NR4A1 and breast cancer: Meta‐analyses of adjuvant chemotherapy trials have consistently demonstrated a significant overall survival (OS) benefit of adjuvant chemo plus endocrine therapy (CET) in women with hormone receptor positive (HR+) BC across different age groups, with a greater benefit observed for poly‐chemotherapy regimens that include taxanes and anthracyclines.10